Activation of G-Proteins by Morphine and Codeine Congeners: Insights to the Relevance of O- and N-Demethylated Metabolites at μ- and δ-Opioid Receptors

@article{Thompson2004ActivationOG,
  title={Activation of G-Proteins by Morphine and Codeine Congeners: Insights to the Relevance of O- and N-Demethylated Metabolites at $\mu$- and $\delta$-Opioid Receptors},
  author={Chad M Thompson and Heidi L. Wojno and Elisabeth Greiner and Everette L. May and Kenner C. Rice and Dana E Selley},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2004},
  volume={308},
  pages={547 - 554}
}
Phenotypic differences in analgesic sensitivity to codeine (3-methoxymorphine) results from polymorphisms in cytochrome P450–2D6, which catalyzes O-demethylation of codeine to morphine. However, O-demethylation reportedly is not required for analgesic activity of the 7,8-saturated codeine congeners dihydrocodeine, hydrocodone, and oxycodone. This study determined the potency and efficacy of these compounds and their demethylated derivatives to stimulate μ- and δ-opioid receptor-mediated G… 

Tables from this paper

In vitro and in vivo pharmacological profile of the 5-benzyl analogue of 14-methoxymetopon, a novel μ opioid analgesic with reduced propensity to alter motor function

Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents.

Compound 8 showed improved pharmacological profiles compared to the original lead, acting mainly at peripheral while increasing the intestinal motility in morphine-pelleted mice, and seems to be a more promising lead to develop novel therapeutic agents toward OIC.

Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor

It is shown that the presence of a 6-cyano group in N-methylmorphinans has a strong influence on the binding to the opioid receptors and post-receptor signaling and may aid in identification of opioid therapeutics with enhanced analgesic properties and fewer undesirable effects.

Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists.

Results supported the hypothesis that NAP and NAQ may serve as leads to develop more potent and selective antagonists for the mu opioid receptor and provided two distinguished potential application routes for these two agents and their derivatives.

Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism

It is opine that pharmacogenetic testing, especially for CYP2D6 with considerations of phenoconversion due to concomitant drug administration, should be appraised to improve oxycodone efficacy.

6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand.

  • Dwight A WilliamsYi Zheng Yan Zhang
  • Biology, Chemistry
    ACS chemical neuroscience
  • 2016
Findings suggest that BNAP is a dual MOR antagonist/KOR agonist and may have functional use in irritable bowel patients.

In Vivo Activity of Norhydrocodone: An Active Metabolite of Hydrocodone

Naltrexone did not antagonize opioid-induced seizure activity, suggesting that seizures were not opioid receptor-mediated, and norhydrocodone is an active metabolite of hydrocodones and may contribute to therapeutic and toxic effects following hydrocODone administration.
...

References

SHOWING 1-10 OF 43 REFERENCES

Delta opioid modulation of the binding of guanosine-5'-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects.

The ability of the delta opioid agonist DPDPE to stimulate binding of the GTP analog guanosine-5'-O-(3-[35S]thio)triphosphate to pertussis toxin-sensitive G proteins has been characterized in membranes from NG108-15 mouse neuroblastoma X rat glioma cells.

Codeine O-demethylation: rat strain differences and the effects of inhibitors.

Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.

The ability of mu-opioid agonists to activate G proteins has been demonstrated by studying the binding of the GTP analogue guanosine-5'-O-(3-[35S]thio)triphosphate ([35S]GTP gamma S) to membranes

Affinities of dihydrocodeine and its metabolites to opioid receptors.

It is suggested that dihydromorphine and its 6-O-glucuronide may provide a relevant contribution to the pharmacological effects of dihydrocodeine.

mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy.

The results suggest that mu-opioid agonist efficacy is determined by the magnitude of the receptor-mediated affinity shift in the binding of GTP (or[35S]GTP gamma S) versus GDP to the G protein and by the number of G proteins activated per occupied receptor.

Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity.

Coadministration of codeine with selective inhibitors of CYP3A4 may result in increased morphine production and enhanced pharmacodynamic effects due to shunting down the CYP2D6 pathway.

Mu receptor binding of some commonly used opioids and their metabolites.

Effect of Cytochrome P 450 2 D 1 Inhibition on Hydrocodone Metabolism and its Behavioral Consequences in Rats 1

Data suggest that differences in CYP2D6 phenotype will have limited influence on the drug response to hydrocodone after nonoral administration, and this has recently been verified in a study showing that inhibition of hydrocODone biotransformation to hydromorphone does not affect measures of abuse liability.